NCT05826535 2026-04-17
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT03939026 2026-03-02
ALPHA
Allogene Therapeutics
Phase 1 Completed
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT06285422 2025-11-28
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
Phase 1 Active not recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT05653271 2025-08-11
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
Phase 1 Recruiting
NCT04735471 2025-06-18
GLEAN-1
Adicet Therapeutics
Phase 1 Terminated
NCT05665062 2025-04-06
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
Phase 1 Active not recruiting
NCT04323657 2023-03-16
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
Phase 1/2 Completed
NCT00562965 2018-01-09
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 3 Terminated
NCT00060684 2015-01-19
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
CTI BioPharma
Phase 1 Completed
NCT00850499 2012-12-12
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated